Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.45 |
| ▸ | FNTB | P49356 | 8/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.38 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | GNRHR | P30968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23733466 | 0.87 | FNTA (0.44) | FNTAFNTBNPC1KMT2ANAMPT | |
| SCHEMBL23733472 | 0.85 | FNTA (0.47) | FNTAFNTBKDRNPC1RAB9A | |
| SCHEMBL20203595 | 0.81 | KDR (0.47) | FNTAFNTBKDRKMT2ANAMPT | |
| SCHEMBL18806180 | 0.81 | CDK1 (0.44) | NPC1RAB9AKMT2A | |
| SCHEMBL23733491 | 0.81 | CYP2C19 (0.38) | NPC1RAB9AKMT2A | |
| SCHEMBL20203593 | 0.79 | ALDH1A1 (0.39) | NPC1RAB9AKMT2A | |
| SCHEMBL20203637 | 0.79 | ENPP2 (0.43) | NPC1RAB9AKMT2ANAMPT | |
| SCHEMBL23733468 | 0.79 | NPC1 (0.42) | KDRNPC1 | |
| SCHEMBL20203582 | 0.79 | KDR (0.40) | KDRNPC1 | |
| SCHEMBL22876985 | 0.78 | HDAC3 (0.40) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
| WO-2018097297-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | FNTA 4431/4885FNTB 4849/4885KDR 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.